129 related articles for article (PubMed ID: 22335366)
1. Leuprolide acetate: pharmaceutical use and delivery potentials.
Teutonico D; Montanari S; Ponchel G
Expert Opin Drug Deliv; 2012 Mar; 9(3):343-54. PubMed ID: 22335366
[TBL] [Abstract][Full Text] [Related]
2. Leuprolide acetate: a drug of diverse clinical applications.
Wilson AC; Meethal SV; Bowen RL; Atwood CS
Expert Opin Investig Drugs; 2007 Nov; 16(11):1851-63. PubMed ID: 17970643
[TBL] [Abstract][Full Text] [Related]
3. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL; Brogden RN
Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
[TBL] [Abstract][Full Text] [Related]
4. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
5. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
6. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
7. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
Miller BS; Shukla AR
Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
[TBL] [Abstract][Full Text] [Related]
8. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
[TBL] [Abstract][Full Text] [Related]
10. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
11. [Long-acting depot of LH-RH agonist].
Akaza H
Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
[No Abstract] [Full Text] [Related]
12. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
[TBL] [Abstract][Full Text] [Related]
13. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
14. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
15. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
16. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
17. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.
Mostafa NM; Hosmane B; Larsen LM; Chwalisz K; Chiu YL; Pradhan RS
Clin Drug Investig; 2014 Jul; 34(7):441-8. PubMed ID: 24756362
[TBL] [Abstract][Full Text] [Related]
19. [Leuprorelin acetate depot].
Mashimo T
Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
[No Abstract] [Full Text] [Related]
20. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW; Gruca D; Bacher P
Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
